Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease

Drugs

Volumn 65, Issue SUPPL. 1, 2005, Pages 35-42

  Monés, Joan ^a,b,c  

^a 'Santa Creu I Sant Pau' Hospital   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ANEMIA; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM HEMORRHAGE; DIGESTIVE TRACT ENDOSCOPY; DRUG MEGADOSE; DRUG POTENCY; DYSPHAGIA; EAR; ENVIRONMENT; FREQUENCY ANALYSIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; HEALTH CARE UTILIZATION; HEARTBURN; HISTOPATHOLOGY; HUMAN; LARYNGITIS; LARYNGOPHARYNGEAL REFLUX; MEDICAL INFORMATION; MENTAL DISEASE; MONITORING; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; NOSE; POPULATION; PROGNOSIS; RECURRENT DISEASE; REFLUX ESOPHAGITIS; RELAPSE; REMISSION; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; STANDARD; STOMACH ACID; STOMACH CONTENT; STOMACH MUCOSA; STOMACH PH; TERTIARY HEALTH CARE; THORAX PAIN; THROAT; TREATMENT FAILURE;

ANTI-ULCER AGENTS; ESOPHAGOSCOPY; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMANS; PREDICTIVE VALUE OF TESTS; PROTON PUMPS;

EID: 30344442435     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Locke GR, Talley NJ, Zinsmeister AR, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56
2. Corder AP, Jones RH, Sadler GH, et al. Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice. Br J Clin Pract 1996; 50: 245-8
3. Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Am J Gastroenterol 2001; 96 Suppl 8: S16-8
4. Numans ME, De Wit NJ. Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire. Aliment Pharmacol Therap 2003; 17: 1049-56
5. Jones RH. Gastroesophageal reflux disease in primary care in Europe. Clinical presentation and endoscopic findings. Eur J General Pract 1995; 1: 149-54
6. Ellis KK, Oehlke M, Helfand M, et al. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management? Am J Gastroenterol 1997; 92: 1472-4
7. Howden CW, Castell DO, Cohen S, et al. The rationale for continuous maintenance treatment of reflux oesophagitis. Arch Int Med 1995; 155: 1465-71
8. Dent J, Brun J, Fendrick AM, et al., on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1998; 44 Suppl 2: S1-6
9. Jones RH, Pali A, Hungin S. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995; 1: 149-54
10. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42
11. Ghillebert G, Demeyere AM, Janssens J, et al. How well does quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? Dig Dis Sci 1995; 40: 1317-24
12. Monés J, Clave P, Mearin F. Esophageal pH monitoring: are you sure that the electrode is properly placed? Am J Gastroenterol 2001; 96: 975-8
13. Carlsson R, Dent J, Watts R, et al. Gastroesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24
14. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients of symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161-8
15. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastroesophageal reflux disease. Drugs 2004; 64: 277-95
16. Bate CM, Riley SA, Chapman RW, et al. Evaluation of omeprazole as a cost-effective diagnostic test for gastroesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 59-66
17. Juul-Hansen P, Ryding A, Jacobsen CD, et al. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopicnegative patients. Scand J Gastroenterol 2001; 36: 806-10
18. Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24-h esophageal pH monitoring in diagnosing gastro-esophageal reflux disease in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther 2000; 14: 389-96
19. Johnsson F, Hatlebakk JG, Klintenberg AC, et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand J Gastroenterol 2003; 38: 354-9
20. Juul-Hansen P, Ryding A. Endoscopy-negative reflux disease: what is the value of proton-pump inhibitor test in everyday clinical practice? Scand J Gastroenterol 2003; 38: 1200-3
21. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518-27
22. Summaries for patients. Does symptom response diagnose gastroesophageal reflux disease? Ann Intern Med 2004; 140: I51
23. Vakil N. Test and treat or treat and test in reflux disease? Aliment Pharmacol Ther 2003; 17: 57-60
24. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with non-cardiac chest pain. Gastroenterology 1998; 115: 42-9
25. Xia HH, Lai SK, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopic-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003; 17: 369-77
26. Ahmad I, Batch AJ. Acid reflux management: ENT perspective. J Laryngol Otol 2004; 118: 25-30
27. Sermon F, Vanden Brande S, Roosens B, et al. Is ambulatory 24-h dual-probe pH monitoring useful in suspected ENT manifestations of GERD. Dig Liver Dis 2004; 36: 105-10
28. Galli J, Scarano S, Agostino S, et al. Pharyngolaringeal reflux in outpatient clinical practice: personal experience. Acta Otorhinolaryngol Ital 2003; 23: 38-42
29. Ours TM, Kavuru MS, Schilz RJ, et al. A prospective evaluation of esophageal testing and a double blind randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999; 94: 3131-8
30. DelGaudio JM, Waring JP. Empiric esomeprazole in the treatment of laryngopharyngeal reflux. Laryngoscope 2003; 113: 598-601
31. Brightling CE, Ward R, Goh KL, et al. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999; 160: 406-10
32. American College of Chest Physicians. A consensus panel report of the American College of Chest Physicians. Managing cough as a defense mechanism and as a symptom. Chest 1998; 114: 133S-81S
33. Bilgen C, Ogut F, Kesimli-Dinc H, et al. The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe pH monitoring in laryngopharyngeal reflux. J Laryngol Otol 2003; 117: 386-90